What is Pulmonary Drug Delivery Systems Market?
The Pulmonary Drug Delivery System market is expected to mark significant growth over the forecasted period owing to the increasing prevalence of respiratory diseases, availability of advanced technology, and continuous launch of new products. Pulmonary drug delivery routes present several advantages compared to conventional drug administration, such as fewer systemic side effects than oral or parenteral administration. The systems most commonly used for respiratory delivery, including nebulizers, metered-dose inhalers, and dry powder inhalers, can all be adapted for use with protein/peptide drugs.
The market study is being classified by Type (Metered Dose Inhalers (Manually-Actuated Pressurized Inhaler, Breath-Actuated Pressurized Inhaler), Dry Powder Inhalers (Single-Dose Inhalers, Multi-Dose Inhalers), Nebulizers (Mesh, Pneumatic, Ultrasonic) and Accessories), by Application (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other) and major geographies with country level break-up.
GlaxoSmithKline plc. (United Kingdom), Koninklijke Philips N.V. (Netherlands), Boehringer Ingelheim International GmbH (Germany), 3M (United States), Teva Pharmaceutical Industries Ltd. (Israel), Aerogen Ltd.(Ireland), Hovione (Portugal), Hantel Technologies (United States), H&T Presspart Manufacturing Ltd. (United Kingdom), Philips Respironics (United States), AstraZeneca plc. (United Kingdom) and Novartis AG (Switzerland) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Omron Healthcare (United States) and PARI Respiratory Equipment, Inc (United States).
Leading key players are focusing on strategic partnerships to improve their products and services. Companies are focusing on increasing their client base to strengthen market position and to enhance product & service offerings. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Pulmonary Drug Delivery Systems market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Pulmonary Drug Delivery Systems market by Type, Application and Region.
On the basis of geography, the market of Pulmonary Drug Delivery Systems has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Incidence of Respiratory Diseases
- Rising Preference for Pulmonary Drug Delivery as an Alternate Route of Drug Delivery
- Technological Advancements in Pulmonary Drug Delivery Systems
- Increase in Research and Developments Activities
- Growth Opportunities in Emerging Markets
- Regulatory Issues related to Approval of Pulmonary Drug Delivery Systems
Market Leaders and some development strategies
In May 2017, Koninklijke Philips N.V. entered into a definitive agreement to acquire Respiratory Technologies, Inc. (RespirTech) with an aim to expand its respiratory care product portfolio.
In May 2020, Glenmark Pharmaceuticals announced the launch of a Single Inhaler Triple Therapy AIRZ-FF - a combination of two bronchodilators, Glycopyrronium & Formoterol, and the inhalation corticosteroid Fluticasone propionate, for Chronic Obstructive Pulmonary Disease (COPD)., and In Nov 2019, Drug maker Lupin launched a device to track the usage pattern of metered-dose inhalers (MDI) by patients suffering from chronic respiratory diseases.
In June 2020, researchers from the University of Szeged, Hungary, reported the development of a carrier-based DPI system, which is an interactive physical blend of a surface-modified carrier and a spray-dried drug with a suitable shape and size for the pulmonary application.
Key Target Audience
Manufacturers of Pulmonary Drug Delivery Systems, Distributors & Suppliers of Pulmonary Drug Delivery Systems, Raw Material Suppliers, Research Institutes and Academic Centers, Government Associations, Market Research and Consulting Firms, Venture Capitalists and Investors and Others
Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase